<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>ILC vs IDC â€” Clinical, Molecular & Therapeutic Differences</title>

  <!-- âœ… Global stylesheet -->
  <link rel="stylesheet" href="../../style.css?v=3" />

  <!-- Page-specific styles -->
  <style>
    header{
      /* your header styles here */
    }
  </style>
    header{
      padding:22px; display:flex; align-items:center; justify-content:space-between; gap:12px;
      background: radial-gradient(1200px 200px at 20% -40%, rgba(245,158,11,.15), transparent 70%),
                 radial-gradient(900px 180px at 90% -30%, rgba(96,165,250,.15), transparent 70%);
      border-bottom:1px solid var(--border);
    }
    .title{font-size:22px; font-weight:800; letter-spacing:.2px}
    .chips{display:flex; gap:8px; flex-wrap:wrap}
    .chip{border:1px solid var(--border); padding:6px 10px; border-radius:999px; font-size:12px; color:var(--muted)}
    .legend{display:flex; gap:8px; align-items:center}
    .badge{display:inline-flex; align-items:center; gap:6px; font-weight:700; padding:6px 10px; border-radius:10px; font-size:12px; color:#0b1020; background:white}
    .badge.ilc{background:linear-gradient(135deg,#fde68a,#f59e0b)}
    .badge.idc{background:linear-gradient(135deg,#93c5fd,#3b82f6)}
    .col-label{width:28%} .col-ilc,.col-idc{width:36%}
    .pill{display:inline-flex; align-items:center; gap:6px; border-radius:999px; padding:2px 8px; font-size:12px; font-weight:700}
    .pill.good{background: rgba(16,185,129,.12); border:1px solid rgba(16,185,129,.35)}
    .pill.warn{background: rgba(244,63,94,.12); border:1px solid rgba(244,63,94,.35)}
    .ref{padding:14px 22px; color:var(--muted); font-size:12px}
  </style>
</head>
<body>
  <div class="wrap">
    <header>
      <div>
        <div class="title">ILC vs IDC â€” Differences & Therapeutic Implications</div>
        <div class="chips">
          <span class="chip">ğŸ§¬ CDH1 / E-cadherin</span>
          <span class="chip">ğŸŒ¸ ER-positive predominance</span>
          <span class="chip">ğŸ’Š AI vs Tamoxifen</span>
          <span class="chip">ğŸ§­ Metastatic tropism</span>
        </div>
      </div>
      <div class="legend">
        <span class="badge ilc">ğŸŸ¡ ILC</span>
        <span class="badge idc">ğŸ”µ IDC</span>
      </div>
    </header>

    <!-- Back links -->
    <p class="back"><a href="index.html">â¬…ï¸ Back to Breast Home</a></p>
    <p class="back"><a href="../">â¬…ï¸ Back to Surgery Home</a></p>

    <table role="table" aria-label="ILC vs IDC Comparison">
      <thead>
        <tr>
          <th class="col-label">ğŸ§© Category</th>
          <th class="col-ilc">ğŸŸ¡ ILC</th>
          <th class="col-idc">ğŸ”µ IDC</th>
          <th>ğŸ¯ Therapeutic Implications</th>
        </tr>
      </thead>
      <tbody>
        <!-- Clinical Presentation first -->
        <tr>
          <td>ğŸ©º Example Clinical Presentation</td>
          <td>ğŸ‘µ Postmenopausal, strongly <b>ER+</b>; subtle/asymmetric thickening (ğŸ©» often underestimated); later GI/peritoneal symptoms ğŸ«„</td>
          <td>ğŸ¤ Palpable spiculated mass with clear mammographic correlate; later ğŸ¦´ bone pain</td>
          <td>ğŸ§­ For ILC: obtain <b>breast MRI</b> for extent; anticipate diffuse margins; endocrine-first often reasonable</td>
        </tr>

        <tr>
          <td>ğŸ“Š Prevalence</td>
          <td>~10% of breast cancers</td>
          <td>Most common subtype</td>
          <td>ğŸ“ ILC underrepresented in trials â†’ avoid one-size-fits-all extrapolation</td>
        </tr>

        <tr>
          <td>ğŸ”¬ Morphology</td>
          <td>â€œ<b>Single-file</b>â€ ğŸ§µ non-cohesive cells; hallmark = <b>E-cadherin loss</b> (CDH1) ğŸš«</td>
          <td>Cohesive nests/glands ğŸ§±</td>
          <td>ğŸ” E-cadherin loss aids diagnosis; expect diffuse growth â†’ margin planning matters</td>
        </tr>

        <tr>
          <td>ğŸ§¬ Genomics</td>
          <td>â†‘ <b>CDH1</b>, PTENâ†“/AKTâ†‘, <b>TBX3</b>, <b>FOXA1</b>; â†“ <b>GATA3</b> ğŸ§¬</td>
          <td>More <b>GATA3</b>; rare CDH1 mutation</td>
          <td>Distinct ER co-factor wiring â†’ different endocrine sensitivity/resistance biology</td>
        </tr>

        <tr>
          <td>ğŸŒ¸ Hormone/Proliferation</td>
          <td>Mostly <b>ER+</b>, HER2â€“; low Ki-67 ğŸŒ¿; Luminal-Aâ€“like</td>
          <td>Mixed: Luminal A/B, HER2+, TNBC</td>
          <td><span class="pill good">Endocrine-driven</span> strategy in many ILCs</td>
        </tr>

        <tr>
          <td>ğŸ§­ Metastatic Pattern</td>
          <td>GI ğŸ½ï¸, peritoneum ğŸ«„, ovaries ğŸ¥š â†‘</td>
          <td>Bone ğŸ¦´, lung ğŸŒ¬ï¸, liver ğŸ§« common</td>
          <td>Tailor staging/surveillance; in ILC consider GI/peritoneal evaluation when symptomatic</td>
        </tr>

        <tr>
          <td>ğŸ’‰ Chemo Response (Neoadjuvant)</td>
          <td>Lower pCR (~3â€“5%) âš ï¸; less downstaging; higher positive margins/mastectomy</td>
          <td>Higher pCR (~14%) âœ…; more downstaging & BCS</td>
          <td>ğŸ¯ Use chemotherapy selectively in ILC; prefer biomarker-guided selection</td>
        </tr>

        <tr>
          <td>ğŸ§ª Oncotype DX</td>
          <td>High-risk RS rare (~1.5%); many intermediate ğŸ¤”</td>
          <td>Up to ~20% high RS</td>
          <td>Intermediate RS less informative in ILC â†’ integrate clinicopathologic context</td>
        </tr>

        <tr>
          <td>ğŸ§¿ HER2 & Trastuzumab</td>
          <td>Classic ILC 3â€“5%; mixed/non-classic up to ~9â€“10% â•; <b>trastuzumab effective</b> ğŸ’‰</td>
          <td>~15â€“20%; anti-HER2 standard</td>
          <td>ğŸ§ª Donâ€™t assume HER2â€“ in ILC; test and treat â€” benefit â‰ˆ IDC</td>
        </tr>

        <tr>
          <td>ğŸŒ¡ï¸ Endocrine Therapy</td>
          <td><b>Aromatase inhibitors</b> (e.g., letrozole) &gt; tamoxifen ğŸŸ¢</td>
          <td>AI benefit clearest in Luminal-B; less in Luminal-A</td>
          <td>Postmenopausal ILC: <span class="pill good">prefer AI</span>; monitor TAM resistance mechanisms</td>
        </tr>

        <tr>
          <td>ğŸ“‰ Prognosis</td>
          <td>Often lower grade & slow-growing â³ but risk of <b>late</b> recurrence; occult/diffuse disease & atypical GI/peritoneal mets</td>
          <td>Greater chemo-sensitivity may allow earlier downstaging ğŸ’¥</td>
          <td>ğŸ—ºï¸ ILC: emphasize accurate extent (MRI), margin strategy, endocrine durability, and vigilance for late relapse</td>
        </tr>

        <tr>
          <td>ğŸ§  Buzzwords (Memory Anchors)</td>
          <td>â€œ<b>Single-file</b>â€ ğŸ§µ â€¢ â€œ<b>E-cadherinâˆ’</b>â€ ğŸš« â€¢ â€œ<b>FOXA1/TBX3</b>â€ ğŸ§¬ â€¢ â€œ<b>GI/peritoneal mets</b>â€ ğŸ«„ â€¢ â€œ<b>AI&gt;TAM</b>â€ ğŸ’Š</td>
          <td>â€œ<b>Cohesive glands</b>â€ ğŸ§± â€¢ â€œ<b>GATA3</b>â€ ğŸ§¬ â€¢ â€œ<b>Chemo-responsive</b>â€ ğŸ’¥ â€¢ â€œ<b>Bone/lung/liver</b>â€ ğŸ¦´ğŸŒ¬ï¸ğŸ§«</td>
          <td>Use these as recall triggers on exams/rounds ğŸ”‘</td>
        </tr>
      </tbody>
    </table>

    <div class="ref">
      ğŸ“š Source: Barroso-Sousa R, Metzger-Filho O. <i>Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications.</i> PMCID: PMC4952020, PMID: 27482285.
    </div>
  </div>
</body>
</html>
